5‐Fluorouracil for keloid scars
References
Additional references
Anderson RT, Aaronson JK, Wilkon D. Critical review of the international assessments of health‐related quality of life. Quality of Life Research 1993;2:369‐95.
Bayat A, McGrouther DA, Ferguson MW. Skin scarring. BMJ (Clinical Research Edition) 2003;326(7380):88‐92.
Berman B, Bieley HC. Keloids. Journal of the American Academy of Dermatology1995; Vol. 33, issue 1:117‐23.
Bijlard E, Steltenpool S, Niessen F. Intralesional 5‐Fluorouracil in keloid treatment: a systematic review. Acta Dermato‐Venereologica 2015;95(7):778‐82.
Blit PH, Jeschke MG. Keloids: what do we know and what do we do next?. Translational Research 2012;159(3):173‐4.
Bock O, Schmid‐Ott G, Malewski P, Mrowietz U. Quality of life of patients with keloid and hypertrophic scarring. Archives of Dermatological Research 2006;297(10):433‐8.
Bulstrode NW, Mudera V, McGrouther DA, Grobbelaar AO, Cambrey AD. 5‐Fluorouracil selectively inhibits collagen synthesis. Plastic and Reconstructive Surgery 2005;116(1):209‐21.
Carroll W, Patel K. Steroids and fluorouracil for keloids and hypertrophic scars. JAMA Facial Plastic Surgery 2015;17(2):77‐9.
Chike‐Obi CJ, Cole PD, Brissett AE. Keloids: pathogenesis, clinical features, and management. Seminars in Plastic Surgery 2009;23(3):178‐84.
Deeks JJ, Higgins JP, Altman DG. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Draaijers LJ, Tempelman FR, Botman YA, Tuinebreijer WE, Middelkoop E, Kreis RW, et al. The patient and observer scar assessment scale: a reliable and feasible tool for scar evaluation. Plastic and Reconstructive Surgery 2004;113(7):1960‐5.
Fitzpatrick TB. The validity and practicality of sun‐reactive skin types I through VI. Archives of Dermatology 1988;124(6):869‐71.
Fitzpatrick RE. Treatment of inflamed hypertrophic scars using intralesional 5‐FU. Dermatologic Surgery 1999;25(3):224‐32.
Goldan O, Weissman O, Regev E, Haik J, Winkler E. Treatment of postdermabrasion facial hypertrophic and keloid scars with intralesional 5‐Fluorouracil injections. Aesthetic Plastic Surgery 2008;32(2):389‐92.
GRADE Working Group. GRADEpro Guideline Development Tool. Version last updated December 2015. McMaster University (developed by Evidence Prime, Inc.), 2015.
Gupta S, Kalra A. Efficacy and safety of intralesional 5‐fluorouracil in the treatment of keloids. Dermatology 2002;204(2):130‐2.
Han R, Yang YM, Dietrich J, Luebke A, Mayer‐Pröschel M, Noble M. Systemic 5‐fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. Journal of Biology 2008;7(4):12.
Haurani MJ, Foreman K, Yang JJ, Siddiqui A. 5‐Fluorouracil treatment of problematic scars. Plastic and Reconstructive Surgery 2009;123(1):139‐48.
Higgins JP, Altman DG, Sterne JA. Chapter 8: The Cochrane Collaboration’s tool for assessing risk of bias. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JP, Deeks JJ, Altman DG, editor(s). Chapter 16.4: Cross‐over trials. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Idriss N, Maibach HI. Scar assessment scales: a dermatologic overview. Skin Research and Technology 2009;15:1‐5.
Khare N, Patil SB. A novel approach for management of ear keloids: results of excision combined with 5‐fluorouracil injection. British Journal of Plastic Surgery 2012;65(11):e315‐7.
Kontochristopoulos G, Stefanaki C, Panagiotopoulos A, Stefanaki K, Argyrakos T, Petridis A, et al. Intralesional 5‐fluorouracil in the treatment of keloids: an open clinical and histopathologic study. Journal of the American Academy of Dermatology 2005;52(3):474‐9.
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6:e1000100.
Longley DB, Harkin DP, Johnston PG. 5‐Fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer 2003;3(5):330‐8.
Nanda S, Reddy BS. Intralesional 5‐fluorouracil as a treatment modality of keloids. Dermatological Surgery 2004;30(1):54‐6.
Perdanasari AT, Torresetti M, Grassetti L, Nicoli F, Zhang YX, Dashti T, et al. Intralesional injection treatment of hypertrophic scars and keloids: a systematic review regarding outcomes. Burns & Trauma 2015;3(14):online publication available from burnstrauma.biomedcentral.com/articles/10.1186/s41038‐015‐0015‐7.
Prabhu A, Sreekar H, Uppin VM, Powar R. A randomized controlled trial comparing the efficacy of intralesional 5‐fluorouracil versus triamcinolone acetonide in the treatment of keloids. Journal of the Scientific Society 2012;39(1):19.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Saha AK, Mukhopadhyay M. A comparative clinical study on role of 5‐Flurouracil versus triamcinolone in the treatment of keloids. Indian Journal of Surgery 2012;74(4):326‐9.
Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Seifert O, Mrowietz U. Keloid scarring: bench and bedside. Archives of Dermatological Research 2009;301(4):259‐72.
Shin JY, Kim JS. Could 5‐fluorouracil or triamcinolone be an effective treatment option for keloid after surgical excision? A meta‐analysis. Journal of Oral and Maxillofacial Surgery 2016;74(5):1055‐60.
Scottish Intercollegiate Guidelines Network (SIGN). Search filters. www.sign.ac.uk/methodology/filters.html (accessed 23 January 2017).
Sterne JA, Egger M, Moher D, editor(s). Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Uppal RS, Khan U, Kakar S, Talas G, Chapman P, McGrouther AD. The effects of a single dose of 5‐fluorouracil on keloid scars: a clinical trial of timed wound irrigation after extralesional excision. Plastic and Reconstructive Surgery 2001;108(5):1218‐24.
Wendling J, Marchand A, Mauviel A, Verrecchia F. 5‐fluorouracil blocks transforming growth factor‐beta‐induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c‐Jun NH2‐terminal kinase/activator protein‐1 activation. Molecular Pharmacology 2003;64(3):707‐13.
